Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12604640 | 1.00 | POLB (0.49) | POLBFKBP1AALDH1A1HPGDCHRM2 | |
| SCHEMBL13179991 | 1.00 | POLB (0.49) | POLBFKBP1AALDH1A1HPGDCHRM2 | |
| SCHEMBL20992083 | 0.90 | FKBP1A (0.47) | FKBP1AALDH1A1HPGDCHRM2CHRM4 | |
| SCHEMBL10137746 | 0.85 | CHRM2 (0.47) | POLBFKBP1AALDH1A1HPGDCHRM2 | |
| SCHEMBL7444519 | 0.85 | POLB (0.52) | POLBFKBP1AALDH1A1HPGDCHRM2 | |
| SCHEMBL7444515 | 0.85 | POLB (0.52) | POLBFKBP1AALDH1A1HPGDCHRM2 | |
| SCHEMBL995328 | 0.84 | POLB (0.51) | POLBFKBP1AALDH1A1HPGDCHRM2 | |
| SCHEMBL995331 | 0.84 | POLB (0.51) | POLBFKBP1AALDH1A1HPGDCHRM2 | |
| SCHEMBL995333 | 0.84 | POLB (0.51) | POLBFKBP1AALDH1A1HPGDCHRM2 | |
| SCHEMBL16589450 | 0.84 | ALDH1A1 (0.49) | POLBFKBP1AALDH1A1HPGDFABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233839-B1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-25 | — | — | EP | disclosed |
| US-10202387-B2 | Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN-CILAG (FR) | 2018-03-01 | — | — | US | disclosed |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN-CILAG (FR) | 2018-03-01 | — | — | US | disclosed |
| US-9512074-B2 | Radiolabeled inhibitors of the amino acid transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA (US) | 2016-12-06 | — | — | US | disclosed |
| WO-2016097359-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | WO | disclosed |
| US-20150056138-A1 | Radiolabeled Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA | 2015-02-26 | — | — | US | disclosed |
| US-8895607-B2 | Inhibitors of the amino acid transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130065935-A1 | Novel Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA | 2013-03-14 | — | — | US | disclosed |
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8188311-B2 | L-threonine derivatives of high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-29 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100069446-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069489-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS (US) | 2010-03-18 | — | — | US | disclosed |
| US-7589233-B2 | L-Threonine derivatives of high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2009-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065935-A1 | Novel Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | SLC1A2, SLC1A1, SLC1A3 | POLB 3030/4885FKBP1A 3599/4885ALDH1A1 1325/4885 |
| US-20150056138-A1 | Radiolabeled Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | SLC1A2, SLC1A1, SLC1A3 | POLB 2877/4885FKBP1A 3208/4885ALDH1A1 1172/4885 |
| US-10202387-B2 | Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors | PIK3CB, PIK3CD, PIK3CA | POLB 705/4885FKBP1A 1120/4885ALDH1A1 1880/4885 |
| US-20100069446-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | BCAT1, AADAT, TPI1 | POLB 4813/4885FKBP1A 868/4885ALDH1A1 1176/4885 |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | PIK3CB, PIK3CD, PIK3CA | POLB 705/4885FKBP1A 1120/4885ALDH1A1 1880/4885 |
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | IL4I1, SLC7A1, GOT1 | POLB 4685/4885FKBP1A 777/4885ALDH1A1 945/4885 |
| US-20100069489-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | BCAT1, AADAT, TPI1 | POLB 4813/4885FKBP1A 868/4885ALDH1A1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.